[57 cases of acute leukemia. Trial treatment with a semisynthetic daunorubicin derivative: 22,050 R.P].
D000293:Adolescent; D000328:Adult; D000368:Aged; D001772:Blood Cell Count; D001792:Blood Platelets; D001803:Blood Transfusion; D001856:Bone Marrow Examination; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012075:Remission, Spontaneous; D013610:Tachycardia / Q000139:chemically induced
D003630:Daunorubicin
57 observations de leucémies aiguës. Essai de traitement par un dérivé semi-synthétique de la daunorubicine: le 22 050 R.